Why the study?
Does dexrazoxane reduce cardiotoxicity in patients receiving anthracyclines?
Population
Adult and pediatric patients receiving doxorubicin and other anthracyclines, as well as preclinical models
Design
Review
Authors
Loading...
Supports dexrazoxane for anthracycline cardiotoxicity reduction; leaves open optimal use with modern regimens pending prospective trials.
Does dexrazoxane reduce cardiotoxicity in patients receiving anthracyclines?
Dexrazoxane effectively reduces anthracycline-induced cardiotoxicity by acting as an iron chelator to prevent oxidative stress.
Hasinoff et al. (1998) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: